CorMedix Inc.

As of June 30, 2026, CorMedix Inc. carries a market capitalization of 527.36M, placing it among publicly traded companies globally. Its enterprise value stands at 429.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CorMedix Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, CorMedix Inc. has 77.67M shares outstanding.

As of June 30, 2026, CorMedix Inc. trades at a trailing price-to-earnings ratio of 3.24. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at 1.31.

As of June 30, 2026, CorMedix Inc. trades at an EV/EBITDA multiple of 1.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.26 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. CorMedix Inc. trades at an EV/FCF ratio of 1.94, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 429.73M versus a market cap of 527.36M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CorMedix Inc. maintains a current ratio of 2.56, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.50, indicating elevated leverage, while an interest coverage ratio of 91.25 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CorMedix Inc. posted a return on equity (ROE) of 54.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 47.52 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 32.36, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 45.88, useful for judging operating efficiency across full business cycles. The company generates approximately 2.52M in revenue per employee across its workforce of 159.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.30 indicates how many times CorMedix Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CorMedix Inc. recorded 14.20M in income tax expense. That works out to an effective tax rate of 7.98, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 178.04M, leaving 163.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, CorMedix Inc.'s stock has declined approximately 26.16% over the past 52 weeks. The 50-day moving average sits at 6.88, while the 200-day moving average is 6.65.

Over the twelve months ended June 30, 2026, CorMedix Inc. generated 402.31M in revenue and converted that into 163.83M in net income, yielding earnings per share of 1.79. EBITDA reached 220.88M, while operating income came in at 189.98M.

As of June 30, 2026, CorMedix Inc. holds 224.68M in cash and equivalents against 127.05M in total debt, resulting in a net debt position of -97.63M. Total book value stands at 403.37M, with working capital of 256.60M providing operational flexibility.

CorMedix Inc. produced 222.27M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.08M in capital expenditures, free cash flow totaled 219.19M - equivalent to 2.80 per share.

Over the twelve months ended June 30, 2026, CorMedix Inc. posted a gross margin of 82.68, reflecting its pricing power and cost economics. The operating margin of 47.22 and net profit margin of 40.72 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 35.32, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -21.57, meaning CorMedix Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CorMedix Inc.'s most recent stock split took place on March 26, 2019 with a 5:1 split ratio.

As of June 30, 2026, CorMedix Inc. has an Altman Z-Score of 3.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.